IL103223A - Glial-cell derived neurotrophic factor (gdnf), nucleic acid molecules encoding gdnf and methods and compositions for their use - Google Patents

Glial-cell derived neurotrophic factor (gdnf), nucleic acid molecules encoding gdnf and methods and compositions for their use

Info

Publication number
IL103223A
IL103223A IL10322392A IL10322392A IL103223A IL 103223 A IL103223 A IL 103223A IL 10322392 A IL10322392 A IL 10322392A IL 10322392 A IL10322392 A IL 10322392A IL 103223 A IL103223 A IL 103223A
Authority
IL
Israel
Prior art keywords
gdnf
neurotrophic factor
glial
derived neurotrophic
compositions
Prior art date
Application number
IL10322392A
Other languages
English (en)
Other versions
IL103223A0 (en
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of IL103223A0 publication Critical patent/IL103223A0/xx
Priority to IL12191397A priority Critical patent/IL121913A0/xx
Priority to IL14748802A priority patent/IL147488A0/xx
Publication of IL103223A publication Critical patent/IL103223A/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0085—Brain, e.g. brain implants; Spinal cord
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/808—Materials and products related to genetic engineering or hybrid or fused cell technology, e.g. hybridoma, monoclonal products
    • Y10S530/809—Fused cells, e.g. hybridoma
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/827—Proteins from mammals or birds
    • Y10S530/839—Nerves; brain

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Psychology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Wood Science & Technology (AREA)
  • Psychiatry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Hospice & Palliative Care (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Compounds Of Unknown Constitution (AREA)
IL10322392A 1991-09-20 1992-09-18 Glial-cell derived neurotrophic factor (gdnf), nucleic acid molecules encoding gdnf and methods and compositions for their use IL103223A (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
IL12191397A IL121913A0 (en) 1991-09-20 1997-10-07 Glial derived neurotrophic factor
IL14748802A IL147488A0 (en) 1991-09-20 2002-01-06 Glial derived neurotrophic factor

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US76468591A 1991-09-20 1991-09-20
US77410991A 1991-10-08 1991-10-08
US78842391A 1991-11-06 1991-11-06
US85541392A 1992-03-19 1992-03-19

Publications (2)

Publication Number Publication Date
IL103223A0 IL103223A0 (en) 1993-02-21
IL103223A true IL103223A (en) 2005-06-19

Family

ID=27505700

Family Applications (5)

Application Number Title Priority Date Filing Date
IL10322392A IL103223A (en) 1991-09-20 1992-09-18 Glial-cell derived neurotrophic factor (gdnf), nucleic acid molecules encoding gdnf and methods and compositions for their use
IL12191397A IL121913A0 (en) 1991-09-20 1997-10-07 Glial derived neurotrophic factor
IL14065400A IL140654A0 (en) 1991-09-20 2000-12-31 Glial cell line-derived neurotrophic factor antibody
IL14065300A IL140653A0 (en) 1991-09-20 2000-12-31 Glial cell line-derived neurotrophic factor antibody
IL14748802A IL147488A0 (en) 1991-09-20 2002-01-06 Glial derived neurotrophic factor

Family Applications After (4)

Application Number Title Priority Date Filing Date
IL12191397A IL121913A0 (en) 1991-09-20 1997-10-07 Glial derived neurotrophic factor
IL14065400A IL140654A0 (en) 1991-09-20 2000-12-31 Glial cell line-derived neurotrophic factor antibody
IL14065300A IL140653A0 (en) 1991-09-20 2000-12-31 Glial cell line-derived neurotrophic factor antibody
IL14748802A IL147488A0 (en) 1991-09-20 2002-01-06 Glial derived neurotrophic factor

Country Status (21)

Country Link
US (7) US7226758B1 (de)
EP (2) EP1243652A3 (de)
KR (1) KR100242093B1 (de)
AT (1) ATE275197T1 (de)
AU (2) AU679167B2 (de)
CA (1) CA2119463C (de)
DE (1) DE69233407T2 (de)
DK (1) DK0610254T3 (de)
ES (1) ES2225819T3 (de)
FI (1) FI117556B (de)
GE (1) GEP20002243B (de)
HK (2) HK1017816A1 (de)
HU (2) HU220795B1 (de)
IL (5) IL103223A (de)
MX (1) MX9205293A (de)
NO (1) NO321382B1 (de)
NZ (1) NZ244392A (de)
PT (1) PT100879B (de)
SG (1) SG48145A1 (de)
TW (1) TW401422B (de)
WO (1) WO1993006116A1 (de)

Families Citing this family (143)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5981165A (en) * 1991-07-08 1999-11-09 Neurospheres Holdings Ltd. In vitro induction of dopaminergic cells
CA2170751A1 (en) * 1993-09-01 1995-03-09 Timothy J. Cunningham Neuron regulatory factor for promoting neuron survival
AU1443095A (en) * 1993-12-22 1995-07-10 University Of Medicine And Dentistry Of New Jersey Novel nucleic acid sequences isolated from glial cells
DK0755446T3 (da) * 1994-04-25 2007-01-29 Genentech Inc Cardiotrophin og anvendelser deraf
US7258983B2 (en) 1994-04-25 2007-08-21 Genentech, Inc. Cardiotrophin-1 compositions and methods for the treatment of tumor
US6472585B1 (en) 1994-04-25 2002-10-29 Genentech, Inc. Cardiotrophin-1 defective mouse
US5534615A (en) * 1994-04-25 1996-07-09 Genentech, Inc. Cardiac hypertrophy factor and uses therefor
US5853385A (en) * 1994-08-26 1998-12-29 Cytotherapeutics, Inc. Encapsulated PC12 cell transplants for treatment of Parkinson's disease
US5733875A (en) * 1994-11-15 1998-03-31 Amgen Inc. Methods of using GDNF as a neuroprotective agent
JP3093974B2 (ja) * 1995-06-27 2000-10-03 住友ベークライト株式会社 神経細胞用培養液、その製造方法及びこれを用いる神経細胞の培養方法
US6743628B1 (en) 1995-08-28 2004-06-01 Washington University Method of cell culture using neurturin
US5739307A (en) * 1995-08-28 1998-04-14 Washington University Polynucleotide encoding neurturin neurotrophic factor
US6184200B1 (en) 1995-09-28 2001-02-06 Amgen Inc. Truncated glial cell line-derived neurotrophic factor
US5731284A (en) * 1995-09-28 1998-03-24 Amgen Inc. Method for treating Alzheimer's disease using glial line-derived neurotrophic factor (GDNF) protein product
US5641750A (en) * 1995-11-29 1997-06-24 Amgen Inc. Methods for treating photoreceptors using glial cell line-derived neurotrophic factor (GDNF) protein product
US5641749A (en) * 1995-11-29 1997-06-24 Amgen Inc. Method for treating retinal ganglion cell injury using glial cell line-derived neurothrophic factor (GDNF) protein product
WO1997019693A1 (en) * 1995-11-29 1997-06-05 Amgen Inc. Method for treating sensory neuropathy using glial cell line-derived neurotrophic factor (gdnf) protein product
US5905027A (en) * 1995-12-27 1999-05-18 Uab Research Foundation Method of diagnosing and treating gliomas
US5837681A (en) * 1996-02-23 1998-11-17 Amgen Inc. Method for treating sensorineural hearing loss using glial cell line-derived neurotrophic factor (GDNF) protein product
US5929041A (en) * 1996-02-23 1999-07-27 Amgen Inc. Method for preventing and treating sensorineural hearing loss and vestibular disorders using glial cell line-derived neurotrophic factor(GDNF) protein product
NZ329482A (en) 1996-03-14 2000-05-26 Univ Washington A growth factor persephin related to the GDNF/neurturin family of growth factors Methods of treating conditions related to persephin deficiency detecting gene alterations and identifying other members of the family are included
DK0888385T3 (da) 1996-03-14 2003-12-15 Genentech Inc GDNF receptor og anvendelser deraf
US7015316B1 (en) 1996-03-14 2006-03-21 Washington University Polynucleotides encoding human persephin and related growth factors
US6222022B1 (en) * 1996-03-14 2001-04-24 Washington University Persephin and related growth factors
US5741778A (en) * 1996-03-19 1998-04-21 Amgen Inc. Method for treating Huntington's disease using glial cell line-derived neurotrophic factor (GDNF) protein product
US6299895B1 (en) 1997-03-24 2001-10-09 Neurotech S.A. Device and method for treating ophthalmic diseases
US6455277B1 (en) * 1996-04-22 2002-09-24 Amgen Inc. Polynucleotides encoding human glial cell line-derived neurotrophic factor receptor polypeptides
US7138251B1 (en) 1996-04-22 2006-11-21 Amgen Inc. Polynucleotides encoding a neurotrophic factor receptor
AU2677797A (en) * 1996-04-25 1997-11-12 Genetic Therapy, Inc. Viral vectors including polynucleotides encoding neurotrophic factors and uses therefor
CA2262884C (en) * 1996-07-29 2004-06-08 Biopharm Gmbh Egf-like factor from chromaffin granules and glia cell-derived neurotrophic factor with survival-promoting activity on daergic neurons
JP2001512306A (ja) 1997-01-08 2001-08-21 ライフ テクノロジーズ，インコーポレイテッド タンパク質の産生方法
US6025157A (en) * 1997-02-18 2000-02-15 Genentech, Inc. Neurturin receptor
US6372453B1 (en) 1997-02-18 2002-04-16 Genetech, Inc. Neurturin receptor
US6777196B2 (en) 1997-02-18 2004-08-17 Genentech, Inc. Neurturin receptor
US7885697B2 (en) 2004-07-13 2011-02-08 Dexcom, Inc. Transcutaneous analyte sensor
US6042579A (en) * 1997-04-30 2000-03-28 Medtronic, Inc. Techniques for treating neurodegenerative disorders by infusion of nerve growth factors into the brain
SI1005358T1 (en) * 1997-07-30 2003-06-30 Amgen Inc. Use of a neurturin protein product for preventing and treating hearing loss
US6043221A (en) * 1997-07-30 2000-03-28 Amgen Inc. Method for preventing and treating hearing loss using a neuturin protein product
CA2299586C (en) * 1997-08-05 2007-09-18 F. Hoffmann-La Roche Ag Human glial cell line-derived neurotrophic factor promoters, vectors containing same, and methods of screening compounds therewith
DK1064376T3 (da) 1998-03-23 2006-07-24 Genentech Inc GFR-alpha3 og dets anvendelser
US7026138B1 (en) 1998-03-23 2006-04-11 Genentech, Inc. Polynucleotides encoding GFRα3
DE19816186A1 (de) * 1998-04-14 1999-10-21 Univ Muenchen L Maximilians GDNF-kodierende DNA, Teile davon und GDNF-Varianten
US6593133B1 (en) 1998-07-06 2003-07-15 Nsgene A/S Neurotrophic factors
US6284540B1 (en) * 1998-09-29 2001-09-04 Washington University Artemin, a novel neurotrophic factor
US7060676B2 (en) 1999-12-20 2006-06-13 Trustees Of Tufts College T. cruzi-derived neurotrophic agents and methods of use therefor
US20040014082A1 (en) * 2000-08-11 2004-01-22 Invitrogen Corporation Highly homogeneous molecular markers for electrophoresis
US6426065B1 (en) * 2000-11-07 2002-07-30 Clairol Incorporated Use of tris(hydroxymethyl)aminomethane in cold permanent waving processes
US7442370B2 (en) 2001-02-01 2008-10-28 Biogen Idec Ma Inc. Polymer conjugates of mutated neublastin
US7276580B2 (en) 2001-03-12 2007-10-02 Biogen Idec Ma Inc. Neurotrophic factors
NZ529126A (en) 2001-03-28 2010-07-30 Biogen Idec Inc Use of neublastin polypeptides for treating allodynia, hyperalgesic pain and phantom pain
US20030050273A1 (en) * 2001-08-29 2003-03-13 Keiya Ozawa Compositions and methods for treating neurodegenerative diseases
US8364229B2 (en) * 2003-07-25 2013-01-29 Dexcom, Inc. Analyte sensors having a signal-to-noise ratio substantially unaffected by non-constant noise
US7613491B2 (en) * 2002-05-22 2009-11-03 Dexcom, Inc. Silicone based membranes for use in implantable glucose sensors
US20030228295A1 (en) * 2002-04-25 2003-12-11 Svendsen Clive N. Use of human neural stem cells secreting GDNF for treatment of parkinson's and other neurodegenerative diseases
US20060088899A1 (en) * 2002-05-31 2006-04-27 Alvarez Vernon L Combination chemotherapy with chlorotoxin
US7528112B2 (en) 2002-11-15 2009-05-05 Drexel University Small survival-promoting/immunomodulatory peptide for treatment of brain damage, neurodegenerative disorders, and inflammatory disorders
US7388079B2 (en) * 2002-11-27 2008-06-17 The Regents Of The University Of California Delivery of pharmaceutical agents via the human insulin receptor
US20050048041A1 (en) * 2003-01-13 2005-03-03 Rao Mahendra S. Persistent expression of candidate molecule in proliferating stem and progenitor cells for delivery of therapeutic products
EP1587545A2 (de) * 2003-01-13 2005-10-26 Mahendra S. Rao Anhaltende expression von molekülkandidaten in proliferierenden stamm- und vorläuferzellen zur abgabe von therapeutischen produkten
US20040209810A1 (en) * 2003-02-24 2004-10-21 Gill Steven S. Method of treating Parkinson's disease in humans by intraputaminal infusion of glial cell-line derived neurotrophic factor
US8946151B2 (en) 2003-02-24 2015-02-03 Northern Bristol N.H.S. Trust Frenchay Hospital Method of treating Parkinson's disease in humans by convection-enhanced infusion of glial cell-line derived neurotrophic factor to the putamen
NZ543365A (en) 2003-04-18 2009-02-28 Biogen Idec Inc Polymer-conjugated glycosylated neublastin
US7875293B2 (en) * 2003-05-21 2011-01-25 Dexcom, Inc. Biointerface membranes incorporating bioactive agents
EP1636260B1 (de) 2003-06-10 2009-02-18 Nsgene A/S Verbesserte sezernierung von neublastin
EP1648298A4 (de) * 2003-07-25 2010-01-13 Dexcom Inc Sauerstoffverbessernde membransysteme für implantierbare vorrichtungen
US9763609B2 (en) 2003-07-25 2017-09-19 Dexcom, Inc. Analyte sensors having a signal-to-noise ratio substantially unaffected by non-constant noise
US9135402B2 (en) 2007-12-17 2015-09-15 Dexcom, Inc. Systems and methods for processing sensor data
US7591801B2 (en) 2004-02-26 2009-09-22 Dexcom, Inc. Integrated delivery device for continuous glucose sensor
US7920906B2 (en) 2005-03-10 2011-04-05 Dexcom, Inc. System and methods for processing analyte sensor data for sensor calibration
WO2005021065A2 (en) * 2003-08-29 2005-03-10 New York University Indirect delivery of growth factors into the central nervous system
EP1660659A2 (de) * 2003-09-05 2006-05-31 Licentia, Ltd. Mit gdnf verwandte neuropeptide
US7598059B2 (en) 2003-10-02 2009-10-06 Biogen Idec Ma Inc. Neublastin expression constructs
CN1897977A (zh) * 2003-10-20 2007-01-17 Ns基因公司 帕金森氏病的体内基因治疗
US9247900B2 (en) 2004-07-13 2016-02-02 Dexcom, Inc. Analyte sensor
US8093205B2 (en) 2003-12-01 2012-01-10 Medtronic, Inc. Method for treating a stroke by implanting a first therapy delivery element in the CNS and a second therapy delivery element in a damaged tissue of the CNS to promote neurogenesis
US20050123526A1 (en) * 2003-12-01 2005-06-09 Medtronic Inc. Administration of growth factors for neurogenesis and gliagenesis
WO2005079257A2 (en) * 2004-02-12 2005-09-01 Dexcom, Inc. Biointerface with macro- and micro- architecture
US20050208090A1 (en) * 2004-03-18 2005-09-22 Medtronic, Inc. Methods and systems for treatment of neurological diseases of the central nervous system
GB2414934A (en) * 2004-06-11 2005-12-14 Gill Steven Streatfield Treatment of Parkinson's disease with GDNF
EP1773401B1 (de) * 2004-06-21 2013-01-02 Medtronic, Inc. Medizinische systeme und verfahren zur abgabe von zusammensetzungen an zellen
US8722862B2 (en) 2004-08-19 2014-05-13 Biogen Idec Ma Inc. Refolding transforming growth factor beta family proteins
EA013565B1 (ru) 2004-08-19 2010-06-30 Байоджен Айдек Ма Инк. Варианты полипептидов нейбластина, способы их получения и их применение
US8133178B2 (en) 2006-02-22 2012-03-13 Dexcom, Inc. Analyte sensor
CA2619017A1 (en) 2005-08-16 2007-02-22 Copenhagen University Gdnf derived peptides
US8741260B2 (en) * 2005-10-07 2014-06-03 Armagen Technologies, Inc. Fusion proteins for delivery of GDNF to the CNS
US8053569B2 (en) * 2005-10-07 2011-11-08 Armagen Technologies, Inc. Nucleic acids encoding and methods of producing fusion proteins
US8124095B2 (en) * 2005-10-07 2012-02-28 Armagen Technologies, Inc. Fusion proteins for delivery of erythropoietin to the CNS
AU2006308312A1 (en) * 2005-10-28 2007-05-03 Nsgene A/S Implantable Biocompatible Immunoisolatory Vehicle for Delivery of GDNF
ATE480559T1 (de) * 2005-12-14 2010-09-15 Licentia Ltd Verwendungen eines neurotrophischen faktors
TWI501774B (zh) 2006-02-27 2015-10-01 Biogen Idec Inc 神經性病症之治療
WO2007120381A2 (en) * 2006-04-14 2007-10-25 Dexcom, Inc. Analyte sensor
DK2019683T4 (da) 2006-04-25 2022-08-29 Univ California Indgivelse af vækstfaktorer til behandling af CNS-lidelser
WO2007127839A2 (en) * 2006-04-26 2007-11-08 The Regents Of The University Of California Compositions and methods for convection enhanced delivery of high molecular weight neurotherapeutics
EP1872790A1 (de) 2006-06-26 2008-01-02 DeveloGen Aktiengesellschaft Neue Zusammensetzung zur Erhöhung der Bioverfügbarkeit von Neurturin
US8759297B2 (en) * 2006-08-18 2014-06-24 Armagen Technologies, Inc. Genetically encoded multifunctional compositions bidirectionally transported between peripheral blood and the cns
KR100770440B1 (ko) * 2006-08-29 2007-10-26 삼성전기주식회사 질화물 반도체 발광소자
US8637459B2 (en) 2006-11-08 2014-01-28 Emory University Enhancing a population of insulin releasing cells using GFR-A1 agonists
TWI445544B (zh) 2007-05-01 2014-07-21 Biogen Idec Inc 增進血管形成之組合物及方法
US20090011040A1 (en) * 2007-05-02 2009-01-08 Naash Muna I Use of compacted nucleic acid nanoparticles in non-viral treatments of ocular diseases
US20200037874A1 (en) 2007-05-18 2020-02-06 Dexcom, Inc. Analyte sensors having a signal-to-noise ratio substantially unaffected by non-constant noise
WO2008157288A2 (en) 2007-06-13 2008-12-24 Wayne State University Board Of Governors A baclofen solution for low-volume therapeutic delivery
WO2008157308A2 (en) * 2007-06-13 2008-12-24 Wayne State University Board Of Governors A zwitterion solution for low-volume therapeutic delivery
CA2694762A1 (en) 2007-07-27 2009-02-05 Armagen Technologies, Inc. Methods and compositions for increasing alpha-l-iduronidase activity in the cns
EP4098177A1 (de) 2007-10-09 2022-12-07 DexCom, Inc. Integriertes insulin-abgabesystem mit kontinuierlichem glucosesensor
US8417312B2 (en) 2007-10-25 2013-04-09 Dexcom, Inc. Systems and methods for processing sensor data
FI20070808A0 (fi) 2007-10-25 2007-10-25 Mart Saarma GDNF:n silmukointivariantit ja niiden käytöt
US9839395B2 (en) 2007-12-17 2017-12-12 Dexcom, Inc. Systems and methods for processing sensor data
GB0803352D0 (en) 2008-02-22 2008-04-02 Ntnu Technology Transfer As Oligopeptidic compounds and uses thereof
US20090247855A1 (en) 2008-03-28 2009-10-01 Dexcom, Inc. Polymer membranes for continuous analyte sensors
FI20080326A0 (fi) 2008-04-30 2008-04-30 Licentia Oy Neurotroofinen tekijä MANF ja sen käytöt
CA2724384A1 (en) 2008-05-15 2009-11-19 Transmolecular, Inc. Treatment of metastatic tumors
EP2396408B1 (de) 2009-02-12 2017-09-20 CuRNA, Inc. Behandlung von erkrankungen im zusammenhang mit dem neurotrophen faktor gdnf mittels hemmung des natürlichen antisense-transkripts gegen gdnf
CA2748889A1 (en) 2009-03-18 2010-09-23 Armagen Technologies, Inc. Compositions and methods for blood-brain barrier delivery of igg-decoy receptor fusion proteins
US20110002897A1 (en) 2009-06-11 2011-01-06 Burnham Institute For Medical Research Directed differentiation of stem cells
ES2725200T3 (es) 2009-10-09 2019-09-20 Armagen Inc Métodos y composiciones para aumentar la actividad de iduronato 2-sulfatasa en el SNC
WO2011064437A2 (es) 2009-11-26 2011-06-03 Proyecto De Biomedicina Cima, S.L. Vectores virales y procedimientos útiles en la preparación de gdnf
DK2531206T3 (en) 2010-02-04 2017-09-11 Morphotek Inc CHLOROTOXIN POLYPEPTIDES AND CONJUGATES AND USE THEREOF
KR101972173B1 (ko) 2010-05-11 2019-04-24 프레드 헛친슨 켄서 리서치 센터 클로로톡신 변이체, 접합체, 및 이의 사용 방법
MX2013006216A (es) 2010-12-02 2013-10-17 Neurotech Usa Inc Lineas celulares que secretan andamios de anticuerpos anti-angionicos y receptores solubles y sus usos.
UA112981C2 (uk) 2011-04-11 2016-11-25 Елі Ліллі Енд Компані Варіант людського gdnf
US20130053666A1 (en) 2011-08-26 2013-02-28 Dexcom, Inc. Polymer membranes for continuous analyte sensors
EP4338797A3 (de) 2011-12-02 2024-06-12 Armagen, Inc. Verfahren und zusammensetzungen zur erhöhung der arylsulfatase-a-aktivität im zns
US9788765B2 (en) 2012-09-28 2017-10-17 Dexcom, Inc. Zwitterion surface modifications for continuous sensors
CA2913029A1 (en) 2012-12-10 2014-06-19 Fred Hutchinson Cancer Research Center Lipocalin fusion partners
US9737250B2 (en) 2013-03-15 2017-08-22 Dexcom, Inc. Membrane for continuous analyte sensors
EP2968462B1 (de) 2013-03-15 2020-12-23 The Jackson Laboratory Verfahren zur förderung von wundheilung und haarwachstum
US11559580B1 (en) 2013-09-17 2023-01-24 Blaze Bioscience, Inc. Tissue-homing peptide conjugates and methods of use thereof
US10369329B2 (en) 2014-01-30 2019-08-06 Renishaw Plc Neurosurgical apparatus and method
CN106460062A (zh) 2014-05-05 2017-02-22 美敦力公司 用于scd、crt、crt‑d或sca治疗识别和/或选择的方法和组合物
US10538589B2 (en) 2015-01-14 2020-01-21 Armagen Inc. Methods and compositions for increasing N-acetylglucosaminidase (NAGLU) activity in the CNS using a fusion antibody comprising an anti-human insulin receptor antibody and NAGLU
GB201506052D0 (en) 2015-04-09 2015-05-27 Renishaw Plc Movement disorder
CA2986769A1 (en) 2015-05-27 2016-12-01 Neurotech Usa, Inc. Use of encapsulated cell therapy for treatment of ophthalmic disorders
JP6983765B2 (ja) 2015-12-30 2021-12-17 デックスコム・インコーポレーテッド 分析物センサのための酵素固定化接着層
WO2017181149A1 (en) 2016-04-15 2017-10-19 Blaze Bioscience, Inc. Methods of treating breast cancer
EP3538560A4 (de) 2016-11-10 2020-06-17 Keros Therapeutics, Inc. Gdnf-fusionspolypeptide und verfahren zur verwendung davon
EP4307999A1 (de) 2021-03-19 2024-01-24 Dexcom, Inc. Wirkstofffreisetzende membran für analytsensor
AU2022345089A1 (en) 2021-09-15 2024-05-02 Dexcom, Inc. Bioactive releasing membrane for analyte sensor
EP4442830A1 (de) 2021-11-29 2024-10-09 Shanghai Regenelead Therapies Co., Ltd. Aadc/gdnf-polynukleotid und verwendung davon bei der behandlung von morbus parkinson
CA3228457A1 (en) 2022-02-02 2023-08-10 Dexcom, Inc. Sensing systems and methods for diagnosing, staging, treating, and assessing risks of liver disease using monitored analyte data
WO2023164584A1 (en) 2022-02-23 2023-08-31 Dexcom, Inc. Sensing systems and methods for providing decision support around kidney health and/or diabetes
US20230389844A1 (en) 2022-06-01 2023-12-07 Dexcom, Inc. Sensing systems and methods for diagnosing kidney disease
US20240090802A1 (en) 2022-09-02 2024-03-21 Dexcom, Inc. Continuous analyte sensor devices and methods
WO2024145651A1 (en) 2022-12-30 2024-07-04 Dexcom, Inc. Sensing systems and methods for hybrid glucose and ketone monitoring

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4518526A (en) * 1982-12-22 1985-05-21 Genentech, Inc. Purification and activity assurance of precipitated heterologous proteins
EP0154434B1 (de) 1984-02-17 1993-01-27 Genentech, Inc. Menschlicher Transformationswachstumsfaktor und Vorläufer oder Fragment hiervon, Zellen, DNA, Vektoren und Verfahren zu ihrer Herstellung, Zusammensetzungen und Produkte, die diese enthalten, sowie davon abgeleitete Antikörper und Diagnostizierverfahren
US4886747A (en) 1985-03-22 1989-12-12 Genentech, Inc. Nucleic acid encoding TGF-β and its uses
US5284763A (en) 1985-03-22 1994-02-08 Genentech, Inc. Nucleic acid encoding TGF-β and its uses
US5374548A (en) 1986-05-02 1994-12-20 Genentech, Inc. Methods and compositions for the attachment of proteins to liposomes using a glycophospholipid anchor
US5089396A (en) 1985-10-03 1992-02-18 Genentech, Inc. Nucleic acid encoding β chain prodomains of inhibin and method for synthesizing polypeptides using such nucleic acid
US5427780A (en) 1985-10-30 1995-06-27 Biogen, Inc. Composition comprising Mullerian inhibiting substance-like polypeptides
EP0233838A3 (de) * 1986-02-04 1990-01-31 Incyte Pharmaceuticals, Inc. Neuriten stimulierender Faktor und Prozess für seine Herstellung
US5187076A (en) * 1986-07-01 1993-02-16 Genetics Institute, Inc. DNA sequences encoding BMP-6 proteins
US4892538A (en) 1987-11-17 1990-01-09 Brown University Research Foundation In vivo delivery of neurotransmitters by implanted, encapsulated cells
US5106627A (en) 1987-11-17 1992-04-21 Brown University Research Foundation Neurological therapy devices
US5158881A (en) * 1987-11-17 1992-10-27 Brown University Research Foundation Method and system for encapsulating cells in a tubular extrudate in separate cell compartments
US5283187A (en) 1987-11-17 1994-02-01 Brown University Research Foundation Cell culture-containing tubular capsule produced by co-extrusion
US5324819A (en) 1988-04-08 1994-06-28 Stryker Corporation Osteogenic proteins
US5011472A (en) 1988-09-06 1991-04-30 Brown University Research Foundation Implantable delivery system for biological factors
US5250414A (en) 1988-11-04 1993-10-05 Erziehungsdirektion Of The Canton Zurich Diagnostic methods using neurite growth regulatory factors
KR100196540B1 (ko) 1988-11-04 1999-06-15 마틴 이. 샤브 축색성장 조절인자
US5225538A (en) 1989-02-23 1993-07-06 Genentech, Inc. Lymphocyte homing receptor/immunoglobulin fusion proteins
US5017735A (en) 1989-07-24 1991-05-21 Catalytica, Inc. Selective sorption of 2,6-diisopropylnaphthalene
AU6174490A (en) * 1989-08-04 1991-03-11 Board Of Regents, The University Of Texas System Methods and compositions; purified preparation of neural progenitor regulatory factor
CA2064787A1 (en) * 1989-08-11 1991-02-12 Joe E. Springer Dopaminergic neurotrophic factor for treatment of parkinson's disease
US5215969A (en) 1989-08-11 1993-06-01 Hahnemann University Dopaminergic neurotrophic factor for treatment of Parkinson's disease
WO1991010470A1 (en) 1990-01-08 1991-07-25 Brown University Research Foundation Devices and methods for enhanced delivery of active factors
US5270181A (en) 1991-02-06 1993-12-14 Genetics Institute, Inc. Peptide and protein fusions to thioredoxin and thioredoxin-like molecules

Also Published As

Publication number Publication date
SG48145A1 (en) 1998-04-17
FI941285A (fi) 1994-03-18
HUT66137A (en) 1994-09-28
HK1017816A1 (en) 1999-11-26
HU9400717D0 (en) 1994-06-28
EP0610254B1 (de) 2004-09-01
TW401422B (en) 2000-08-11
GEP20002243B (en) 2000-09-25
MX9205293A (es) 1993-05-01
NO321382B1 (no) 2006-05-02
PT100879A (pt) 1994-02-28
CA2119463A1 (en) 1993-04-01
AU679167B2 (en) 1997-06-26
FI117556B (fi) 2006-11-30
PT100879B (pt) 1999-08-31
ES2225819T3 (es) 2005-03-16
EP1243652A3 (de) 2003-03-26
US20020197675A1 (en) 2002-12-26
AU694387B2 (en) 1998-07-16
US7226758B1 (en) 2007-06-05
DE69233407D1 (de) 2004-10-07
KR940702505A (ko) 1994-08-20
EP0610254A4 (de) 1995-05-03
AU2681192A (en) 1993-04-27
US6093802A (en) 2000-07-25
IL140654A0 (en) 2002-02-10
US6362319B1 (en) 2002-03-26
HK1047438A1 (zh) 2003-02-21
CA2119463C (en) 2003-09-16
EP0610254A1 (de) 1994-08-17
FI941285A0 (fi) 1994-03-18
NZ244392A (en) 1995-03-28
NO940922L (no) 1994-05-19
HU220795B1 (hu) 2002-05-28
US6015572A (en) 2000-01-18
HU211984A9 (en) 1996-01-29
IL121913A0 (en) 1998-03-10
IL103223A0 (en) 1993-02-21
IL140653A0 (en) 2002-02-10
WO1993006116A1 (en) 1993-04-01
DK0610254T3 (da) 2005-01-10
US5935795A (en) 1999-08-10
NO940922D0 (no) 1994-03-15
KR100242093B1 (ko) 2000-02-01
EP1243652A2 (de) 2002-09-25
IL147488A0 (en) 2002-08-14
ATE275197T1 (de) 2004-09-15
DE69233407T2 (de) 2005-09-08
AU1900197A (en) 1997-09-18
US6221376B1 (en) 2001-04-24

Similar Documents

Publication Publication Date Title
IL103223A (en) Glial-cell derived neurotrophic factor (gdnf), nucleic acid molecules encoding gdnf and methods and compositions for their use
RU2346951C2 (ru) Выделенный полипептид, связывающий рецептор zalpha11-лиганда (варианты), кодирующий его полинуклеотид (варианты), вектор экспрессии (варианты) и клетка-хозяин (варианты)
HUP9904239A2 (hu) Fehérjék nagymértékű expressziója
EP0653940A4 (de) Glialmitogene faktoren, ihre herstellung und verwendung.
IL173399A0 (en) Circular dna molecule with conditional origin of replication which contains nucleic acid of interest and selection marker but does not encode its replication initiation protein, method for preparing the same and use thereof in gene therapy
DE69229572D1 (de) Gliazellen-aktivierender Faktor und dessen Herstellung
BG101408A (en) Analogs of keratinocyte growth factor
WO2000034474A3 (en) Growth factor homolog zvegf3
DE3751632D1 (de) Expression von biologisch-aktiven PDGF-Analogen in eukaryotischen Zellen
IE871871L (en) Cloning and expression of acidic fibroblast growth factor
EP0479071A3 (en) Polypeptide
ATE346919T1 (de) Nebenhoden-spezifisches rezeptorprotein und dessen verwendung
RU96122169A (ru) Нон-сплайсинговые варианты gp350/220
CA2324649A1 (en) Human p51 genes and gene products thereof
KR920003989A (ko) 콘드로모듈린-i 단백질
Bartzatt et al. Isoelectric focusing of Sendai virus protein by chromatofocusing.
Brown et al. 4959353 Promotion of corneal stroma wound healing with human epidermal growth factor prepared from recombinant DNA
Clark et al. 4959455 Primate hematopoietic growth factors IL-3 and pharmaceutical compositions
Baird et al. 4956455 Bovine fibroblast growth factor
Antoniades et al. 4861757 Wound healing and bone regeneration using PDGF and IGF-I
Aviv et al. 4831120 Method for recovering a purified animal growth hormone or polypeptide analog thereof from a bacterial cell
WO2000037682A8 (en) Method for augmenting expression of a foreign gene

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
KB Patent renewed
KB Patent renewed
EXP Patent expired